| scholarly article | Q13442814 |
| P50 | author | Julia Steinberger | Q47701945 |
| P2093 | author name string | Smita Bhatia | |
| Stephen J Forman | |||
| F Lennie Wong | |||
| Liton Francisco | |||
| Richard Sposto | |||
| Saro H Armenian | |||
| Can-Lan Sun | |||
| Seira Kurian | |||
| Jon Sharp | |||
| P2860 | cites work | ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...] | Q22306349 |
| Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens | Q28328148 | ||
| ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Wri | Q31004678 | ||
| Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis | Q34659375 | ||
| Stem cell transplantation: supportive care and long-term complications | Q35006675 | ||
| Nonmalignant late effects after allogeneic stem cell transplantation | Q35038171 | ||
| Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study | Q35628840 | ||
| Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study | Q35847602 | ||
| Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study | Q36141716 | ||
| Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study | Q36155132 | ||
| Anticancer agents and cardiotoxicity | Q36394573 | ||
| Transplantation and aging | Q36571731 | ||
| Malignant neoplasms following bone marrow transplantation. | Q40942327 | ||
| An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. | Q41634377 | ||
| Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. | Q42279363 | ||
| Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction? | Q44019505 | ||
| Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia | Q46443830 | ||
| Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. | Q47949009 | ||
| Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. | Q51988742 | ||
| Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. | Q53378505 | ||
| Quality of life in 244 recipients of allogeneic bone marrow transplantation. | Q53512272 | ||
| Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors | Q63502959 | ||
| Doxorubicin clearance in the obese | Q68489640 | ||
| Tissue disposition of doxorubicin in experimental animals | Q70379166 | ||
| Plasma and Tissue Distribution of Adriamycin in Patients with Pelvic Cancer | Q71092010 | ||
| Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant | Q72377584 | ||
| Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction | Q73690432 | ||
| Cardiac systolic function before and after hematopoietic stem cell transplantation | Q74082720 | ||
| Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997 | Q74460243 | ||
| Doxorubicin-induced cardiomyopathy | Q77323607 | ||
| Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry | Q77941016 | ||
| Predictors for severe cardiac complications after hematopoietic stem cell transplantation | Q79872383 | ||
| Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of | Q80078439 | ||
| Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study | Q80304240 | ||
| Cardiac manifestations of graft-versus-host disease | Q81256833 | ||
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| congestive heart failure | Q19000661 | ||
| P304 | page(s) | 5537-5543 | |
| P577 | publication date | 2008-09-22 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Late congestive heart failure after hematopoietic cell transplantation | |
| P478 | volume | 26 |
| Q33875046 | A new method to facilitate valid and consistent grading cardiac events in childhood cancer survivors using medical records |
| Q35525461 | Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). |
| Q37080913 | Antiangiogenic drugs in ovarian cancer. |
| Q28732371 | Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase |
| Q37229185 | Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation |
| Q48826318 | Cardiac function after hematopoietic cell transplantation: an echocardiographic cross-sectional study in young adults treated in childhood |
| Q38750270 | Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. |
| Q39270177 | Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant. |
| Q37213203 | Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training |
| Q37624268 | Cardiovascular disease in survivors of hematopoietic cell transplantation. |
| Q37390119 | Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role? |
| Q89653416 | Conditional Survival, Cause-specific Mortality, Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation |
| Q37180878 | Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies |
| Q37453118 | Current status on biologic therapies in the treatment of epithelial ovarian cancer |
| Q57459923 | Early and late complications following hematopoietic stem cell transplantation in pediatric patients - A retrospective analysis over 11 years |
| Q37227651 | Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation |
| Q35604039 | Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation |
| Q34288406 | Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation |
| Q37460433 | Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation |
| Q33605306 | Late cardiovascular complications after hematopoietic cell transplantation |
| Q38798042 | Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care |
| Q33705877 | Long-term consequences of hematopoietic stem cell transplantation: current state of the science |
| Q35184667 | Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up |
| Q91639595 | Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO-AML Study |
| Q35153809 | Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). |
| Q33754654 | Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns |
| Q50527749 | Long-term systolic function in children and young adults after hematopoietic stem cell transplant. |
| Q35223947 | NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges |
| Q35762578 | National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pedia |
| Q35549037 | National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage a |
| Q46181268 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. |
| Q30245682 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report |
| Q96304256 | Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach |
| Q37642770 | Pazopanib: therapeutic developments |
| Q33926274 | Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation |
| Q34369800 | Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study |
| Q36478727 | Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation |
| Q52328145 | Readmission prediction via deep contextual embedding of clinical concepts. |
| Q35797623 | Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group |
| Q38937601 | Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation |
| Q37951860 | Recurrent ovarian cancer: when and how to treat |
| Q46774322 | Risk factors affecting cardiac left-ventricular hypertrophy and systolic and diastolic function in the chronic phase of allogeneic hematopoietic cell transplantation |
| Q34717844 | Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors |
| Q44595367 | The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls |
Search more.